| Phase 16 trials |
|
Phase 1
|
NCT05818124 |
Aug 2023 → Jun 2024 |
influenza |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06816030 |
Jun → Aug 2023 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06615869 |
Jan → Feb 2023 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05386758 |
Jun 2022 → Feb 2023 |
impaired renal function disease |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05386589 |
Jun → Dec 2022 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04392219 |
Apr → Aug 2020 |
Coronaviridae infectious disease |
Ridgeback Biotherapeutics, LP |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT04746183 |
Jul 2020 → Mar 2027 expected |
COVID-19 |
University of Liverpool |
Recruiting
|
No outcome recorded
|
| Phase 27 trials |
|
Phase 2
|
NCT06551844 |
Apr 2026 → Dec 2029 expected |
dengue disease, interferon antiviral depressor |
Oxford University Clinical Research Unit, Vietnam |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06488300 |
Jul 2024 → Jan 2027 expected |
respiratory syncytial virus infectious disease |
University of Oxford |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05648448 |
Feb 2023 → Jan 2027 expected |
influenza |
University of Oxford |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05559905 |
Nov 2022 → Apr 2023 |
respiratory syncytial virus infectious disease |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05041907 |
Sep 2021 → Jan 2027 expected |
COVID-19 |
University of Oxford |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04405570 |
Jun 2020 → Feb 2021 |
COVID-19 |
Ridgeback Biotherapeutics, LP |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04405739 |
Jun 2020 → Feb 2022 |
COVID-19 |
Ridgeback Biotherapeutics, LP |
Completed
|
No outcome recorded
|
| Phase 2/33 trials |
|
Phase 2/3
|
NCT05459532 |
Aug 2022 → Jul 2023 |
COVID-19 |
University of Witwatersrand, South Africa |
Completed
|
No outcome recorded
|
|
Phase 2/3
|
NCT04575597 |
Oct 2020 → May 2022 |
COVID-19 |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2/3
|
NCT04575584 |
Oct 2020 → Aug 2021 |
COVID-19 |
Merck Sharp & Dohme LLC |
Terminated
|
No outcome recorded
|
| Phase 34 trials |
|
Phase 3
|
NCT06667700 |
Dec 2024 → Jan 2031 expected |
COVID-19 |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05595824 |
Dec 2021 → Mar 2022 |
COVID-19 |
Promomed, LLC |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04939428 |
Aug 2021 → Nov 2022 |
COVID-19 |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04730206 |
Jun 2021 → Jul 2022 |
COVID-19 |
KU Leuven |
Terminated
|
No outcome recorded
|